Ubs Oconnor LLC Astrazeneca PLC Transaction History

Ubs Oconnor LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$61.03 - $69.57 $1.36 Million - $1.55 Million	22,217 Added 69.28%	54,284 $3.68 Million
Q4 2023 Feb 14, 2024	SELL	$61.89 - $69.28 $1.08 Million - $1.21 Million	-17,475 Reduced 35.27%	32,067 $2.16 Million
Q3 2023 Nov 14, 2023	BUY	$64.85 - $71.7 $1.04 Million - $1.15 Million	16,000 Added 47.7%	49,542 $3.35 Million
Q2 2023 Aug 14, 2023	BUY	$69.91 - $75.81 $2.34 Million - $2.54 Million	33,542 New	33,542 $2.4 Billion
Q1 2023 May 15, 2023	BUY	$63.15 - $71.6 $893,698 - $1.01 Million	14,152 Added 45.58%	45,200 $3.14 Million
Q4 2022 Feb 14, 2023	SELL	$54.21 - $70.44 $3.54 Million - $4.61 Million	-65,382 Reduced 67.8%	31,048 $0
Q3 2022 Nov 14, 2022	BUY	$53.02 - $135.75 $795,300 - $2.04 Million	15,000 Added 18.42%	96,430 $5.29 Billion
Q2 2022 Aug 12, 2022	BUY	$59.26 - $71.14 $1.99 Million - $2.39 Million	33,589 Added 70.21%	81,430 $5.38 Million
Q1 2022 May 16, 2022	SELL	$55.72 - $67.12 $2.91 Million - $3.5 Million	-52,159 Reduced 52.16%	47,841 $3.17 Million
Q1 2019 May 13, 2019	BUY	$35.49 - $43.02 $3.55 Million - $4.3 Million	100,000 New	100,000 $0

1,361

475M

5.39M

3.75M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $200B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.